ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Letter to HCFA Outlines Positions, Offers Glimpse of Tactics

September 27, 1996

Prevention Trials Should Get More Funding, Coltman Says.

May 18, 2001

NIH Director Zerhouni to discuss Roadmap initiatives Feb. 27.

February 20, 2004

Guest Editorial: Learning from the Power Morcellation Fiasco: Government Must Do More to Regulate Devices

September 12, 2014

DoD Ovarian Cancer Research Program seeks proposals for FY05 funding.

October 1, 2004

QOL Of Anemic Patients Improved With Darbepoetin

June 28, 2002